Health
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer – Small Caps
New research describing the fundamental biology behind Amplia Therapeutics’ (ASX: ATX) planned phase 2 clinical trial on pancreatic…
New research describing the fundamental biology behind Amplia Therapeutics (ASX: ATX) planned phase 2 clinical trial on pancreatic cancer patients has highlighted the potential benefits of using a focal adhesion kinase (FAK) inhibitor prior to administering…
-
Noosa News15 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General13 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
Noosa News23 hours agoInquest into Rosemarie Campbell’s death three days after gastric bypass surgery hears of ‘massive loss’ to family
-
General21 hours agoQueensland announced as 2027 Women’s Softball World Cup host in first Australian event since 1965